These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7202937)

  • 1. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers.
    Uribe M; Casian C; Rojas S; Sierra JG; Go VL
    Gastroenterology; 1981 Apr; 80(4):661-5. PubMed ID: 7202937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
    Schalm SW; Summerskill WH; Go VL
    Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects.
    Uribe M; Go VL; Kluge D
    J Clin Gastroenterol; 1984 Aug; 6(4):331-5. PubMed ID: 6481116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive treatment policies. A) Glucocorticoids: absorption of prednisolone. I. The effect of fasting, food, and food combined with antacids.
    Bergrem H; Djøseland O; Jervell J; Rugstad HE
    Scand J Urol Nephrol Suppl; 1981; 64():167-73. PubMed ID: 6959258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of antacids on the bioavailability of glibenclamide.
    Zuccaro P; Pacifici R; Pichini S; Avico U; Federzoni G; Pini LA; Sternieri E
    Drugs Exp Clin Res; 1989; 15(4):165-9. PubMed ID: 2505996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of effect of sucralfate on prednisone bioavailability.
    Gambertoglio JG; Romac DR; Yong CL; Birnbaum J; Lizak P; Amend WJ
    Am J Gastroenterol; 1987 Jan; 82(1):42-5. PubMed ID: 3799579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease.
    Uribe M; Summerskill WH; Go VL
    Clin Pharmacokinet; 1982; 7(5):452-9. PubMed ID: 7140120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.
    Uribe M; Schalm SW; Summerskill WH; Go VL
    Gut; 1978 Dec; 19(12):1131-5. PubMed ID: 744499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impairment of captopril bioavailability by concomitant food and antacid intake.
    Mäntylä R; Männistö PT; Vuorela A; Sundberg S; Ottoila P
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):626-9. PubMed ID: 6389377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers].
    Etienne SD; Vandermeersch V; Chosidow O; Vu-Thi-My-Le C; Godeau P; Diquet B; Herson S
    Ann Med Interne (Paris); 1990; 141(6):507-11. PubMed ID: 2285202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antacids in reducing digestive disturbances in patients treated with prednisone and prednisolone.
    BOLAND EW
    Calif Med; 1958 Oct; 89(4):262-6. PubMed ID: 13585144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced oral itraconazole bioavailability by antacid suspension.
    Lohitnavy M; Lohitnavy O; Thangkeattiyanon O; Srichai W
    J Clin Pharm Ther; 2005 Jun; 30(3):201-6. PubMed ID: 15896236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic comparison of two oral liquid glucocorticoid formulations.
    Kamada AK; Wiener MB; LaVallee NM; Scott MB; Selner JC; Szefler SJ
    Pharmacotherapy; 1997; 17(2):353-6. PubMed ID: 9085328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid pharmacokinetics in liver disease.
    Uribe M; Go VL
    Clin Pharmacokinet; 1979; 4(3):233-40. PubMed ID: 383357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nature and prognostic significance of serial amino acid determinations in severe chronic active liver disease.
    McCullough AJ; Czaja AJ; Jones JD; Go VL
    Gastroenterology; 1981 Oct; 81(4):645-52. PubMed ID: 7262510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis.
    Trouillot TE; Shrestha R; Kam I; Wachs M; Everson GT
    Liver Transpl Surg; 1999 Sep; 5(5):375-80. PubMed ID: 10477838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of antibodies to Chang liver cell in sera from patients with chronic liver diseases by 125I-labelled protein A binding assay and the effect of prednisolone and 6-mercaptopurine treatment on the level of the antibodies.
    Inagaki Y; Morizane T; Matsumura S; Kawamura N; Watanabe T; Kumagai N; Nakamura T; Tsuchimoto K; Tsuchiya M
    Clin Exp Immunol; 1984 Jul; 57(1):79-84. PubMed ID: 6540149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review.
    Gambertoglio JG; Amend WJ; Benet LZ
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):1-52. PubMed ID: 6991663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.